60 completed, 42 recruiting, 25 not yet recruiting, 22 active not recruiting. 95 Phase 2, 69 Phase 1, 36 Phase 3.
Follow Akeso: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Spontaneous Urticaria AK139, Placebo - Chronic Spontaneous Urticaria | Phase 2 | Not yet recruiting | Akeso | 201 | 2026-10-21 | 2026-10-15 |
| A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis. AK139, Placebo - Prurigo Nodularis (PN) | Phase 2 | Not yet recruiting | Akeso | 132 | 2026-10-01 | 2026-10-20 |
| A Study of AK157D1 for Injection in Advanced Solid Tumors AK157D1 for injection - Advanced Solid Tumors | Phase 1 | Recruiting | Akeso | 243 | 2026-09-30 | 2026-10-13 |
| Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma Cadonilimab, CAPOX regimen, Nivolumab - Gastric / Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | Akeso | 900 | 2026-09-24 | 2026-09-29 |
| A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps AK139, Placebo - Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Phase 2 | Not yet recruiting | Akeso | 75 | 2026-08-10 | 2026-08-10 |
| A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer AK146D1 for injection, AK112 Injection - Advanced Breast Cancer | Phase 2 | Recruiting | Akeso | 200 | 2026-07-17 | 2026-07-22 |
| A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer AK146D1 for injection, AK112 Injection, Platinum chemotherapy - Advanced Non Small Cell Lung Cancer (NSCLC) | Phase 2 | Recruiting | Akeso | 348 | 2026-07-10 | 2026-07-14 |
| A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer AK138D1, Ivonescimab, Carboplatin - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Akeso | 265 | 2026-07-07 | 2026-07-29 |
| A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma AK146D1 for injection, AK112 Injection - Urothelial Carcinoma (UC) | Phase 2 | Not yet recruiting | Akeso | 132 | 2026-06-22 | 2026-06-09 |
| A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer AK138D1, Ivonescimab, treatment of physician's choice - Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Akeso | 286 | 2026-06-06 | 2026-04-30 |
| Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer Anlotinib + Cadonilimab, PULSAR - Previously Treated, Advanced, Biliary Tract Cancers | Phase 2 | Active not recruiting | West China Hospital | 26 | 2026-06-03 | 2026-06-09 |
| A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Participations AK104 (New Site), AK104 (Original Site) - Healthy Male Adults Participants | Phase 1 | Not yet recruiting | Akeso | 158 | 2026-06-01 | 2026-06-01 |
| A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor AK150 - Advanced Malignant Solid Tumors | Phase 1 | Not yet recruiting | Akeso | 96 | 2026-04-30 | 2026-05-05 |
| Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer Cadonilimab (AK104), Oxaliplatin, Capecitabine - Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer | Phase 3 | Recruiting | Akeso | 386 | 2026-04-15 | 2026-04-22 |
| A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis AK139 and placebo, AK139, Placebo - Moderate-to-Severe Atopic Dermatitis | Phase 2 | Not yet recruiting | Akeso | 168 | 2026-04-07 | 2026-03-30 |
| A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma AK104(SC), AK104(IV), Capecitabine - Gastric / Gastroesophageal Junction Adenocarcinoma | Phase 3 | Not yet recruiting | Akeso | 422 | 2026-03-31 | 2026-03-04 |
| ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive) Ivonescimab, Docetaxel, Standard Treatment group - Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs) | Phase 2 | Recruiting | Second Xiangya Hospital of Central South University | 70 | 2026-03-10 | 2026-03-09 |
| A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases VG2025, AK112 - Colorectal Cancer With Hepatic Metastases | Phase 1 / Phase 2 | Not yet recruiting | Akeso | 72 | 2026-03-02 | 2026-01-21 |
| A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis AK139, Placebo - Seasonal Allergic Rhinitis | Phase 2 | Not yet recruiting | Akeso | 111 | 2026-03-02 | 2026-02-27 |
| A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma AK139, Placebo - Asthma | Phase 2 | Not yet recruiting | Akeso | 160 | 2026-02-28 | 2026-02-27 |
Showing 20 of 164. Sign in to see all of them.
Carcinoma, Hepatocellular (9) · Carcinoma, Non-Small-Cell Lung (9) · Dermatitis, Atopic (6) · Uterine Cervical Neoplasms (6) · Nasopharyngeal Carcinoma (4) · Pancreatic Neoplasms (4) · Psoriasis (4) · Biliary Tract Neoplasms (3) · Hypercholesterolemia (3) · Hyperlipidemias (3) · Neoplasms (3) · Ovarian Neoplasms (3) · Asthma (2) · Colorectal Neoplasms (2) · Diabetes Mellitus, Insulin-Dependent, 12 (2)
Carboplatin (20) · Paclitaxel (14) · Cisplatin (11) · Oxaliplatin (11) · Fluorouracil (9) · Pemetrexed (9) · Capecitabine (8) · Docetaxel (8) · Injections (8) · Gemcitabine (7) · Irinotecan (5) · Leucovorin (5) · Azacitidine (4) · Drug Therapy (4) · lenvatinib (4)
China (150) · Australia (7) · United States (6) · Canada (2) · Brazil (1) · France (1) · Germany (1) · Italy (1) · New Zealand (1) · Poland (1) · Spain (1) · United Kingdom (1)
Lin Shen, MD (5) · Li Zhang, MD (4) · Shunchang Jiao, MD (4) · Jiafu Ji, MD (3) · Wenting Li, MD (3) · Xiaozhong Chen, MD (3) · Baohui Han, MD (2) · Chaosu Hu, MD (2) · Guoliang Shao, MD (2) · Hongzhong Jin, MD (2) · Jihui Hao, PhD (2) · Li Bai, MD (2) · Nong Xu, MD (2) · Rui Chen, MD (2) · Ruihua Xu, MD (2)
PMID 35833116, PMID 34327136, PMID 35165764, PMID 36566344, PMID 36569905, PMID 36989884, PMID 37593227, PMID 37677918, PMID 37879536, PMID 37942328, PMID 38110665, PMID 38309287, PMID 38372727, PMID 38820549, PMID 39426385, PMID 39490738, PMID 39843940, PMID 40057343, PMID 40114411, PMID 40297315, PMID 41457351, PMID 41946687, PMID 42218899, PMID 42233228, PMID 42307937, PMID 42409321, PMID 42587052, PMID 42636833